A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of Ravulizumab in Adult Participants with Immunoglobulin A Nephropathy (IgAN)

drug protocol number

D928FC00001

drug sponsor

AstraZeneca

drug study

Ravulizumab

drug trial site

King Faisal Specialist Hospital and Research Center (Riyadh),King Fahad Specialist Hospital (Dammam)

drug status

Ongoing

drug phase